Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
MCLA-129 is a bispecific antibody that binds to and inhibits EGFR and MET, which may lead to inhibition of cell proliferation and tumor regression (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr LB-C07).
|DrugClasses||EGFR Inhibitor (Pan) 54 MET Antibody 20|
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Erlotinib + MCLA-129||Erlotinib MCLA-129||0||0|